TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial - Sims, J R; Zimmer, J A; Evans, C D; Lu, M; Ardayfio, P; Sparks, J; Wessels, A M; Shcherbinin, S; Wang, H; Monkul Nery, E S; Collins, E C; Solomon, P; Salloway, S; Apostolova, L G; Hansson, O; Ritchie, C; Brooks, D A; Mintun, M; Skovronsky, D M (JAMA., 2023)